Welcome to our dedicated page for Medmix news (Ticker: MDMXF), a resource for investors and traders seeking the latest updates and insights on Medmix stock.
medmix AG (MDMXF) is an industrial company specializing in high-precision delivery devices for healthcare, consumer, and industrial end-markets. The medmix news feed on Stock Titan highlights company announcements that cover strategic initiatives, segment performance, and developments across its global production footprint.
Investors and industry observers can use this page to follow corporate updates such as half-year and full-year result releases, where medmix discusses revenue trends, adjusted EBITDA margins, segment gross profit, and cash flow metrics. These communications often explain how the Healthcare segment, including Dental, Drug Delivery, and Surgery business units, and the Consumer & Industrial segment, including Industry and Beauty, are performing and evolving.
News items also include strategic partnerships and expansion projects. For example, medmix has announced a partnership with Gurit, where Gurit’s BondPro adhesive is dispensed using medmix’ MIXPAC greenLine cartridge system, reflecting a focus on sustainable packaging for industrial bonding applications. Other releases describe facility expansions, such as the second production site for Guangdong Qiaoyi Plastic Co. Ltd. in China and the enlarged GEKA do Brasil facility in São Paulo, which support the Beauty business and global customer projects.
Additionally, medmix uses media releases to outline its Growth and Efficiency program, cost measures, and strategic pivot toward high growth and high margin healthcare businesses. By reviewing these updates in one place, readers can track how medmix manages its healthcare, beauty, and industrial activities, and how its global network of 14 production sites and more than 900 active patents supports its long-term positioning. Bookmark this page to access the latest company communications and performance commentary as they are published.
medmix (OTC:MDMXF) reported resilient FY25 results on February 26, 2026: revenue CHF 448.0m (‑4.8% organic, ‑7.4% nominal), gross profit CHF 161.9m (36.1%, +310bps) and adjusted EBITDA CHF 89.7m (20.0%). Net income returned to profit at CHF 7.0m and operating net cash flow was CHF 40.3m. Board proposes a CHF 0.10 dividend; 2026 outlook: flat to low single‑digit organic growth and ~20% adj. EBITDA margin.
Management appointed Sven Luginbühl as CFO and confirmed the Growth & Efficiency program delivering CHF 22.6m savings to date.
medmix (MDMXF) announced two facility expansions to strengthen its Beauty segment: a new 4,000 m² production site for subsidiary Guangdong Qiaoyi in China and a major expansion of GEKA do Brasil in Cotia, Sāo Paulo.
The Qiaoyi plant adds a dedicated injection workshop, AI automation and a 3D warehouse to scale cosmetic packaging output for Asia. The GEKA expansion more than doubled the Brazilian site, insourced warehousing and increased capacity by 25%. medmix said GEKA secured one of its largest single projects, expected to deliver significant revenues in 2026–2027. Both projects emphasize automation and sustainable production.
medmix AG (OTC:MDMXF) has formed a strategic partnership with Gurit to advance sustainable solutions for industrial bonding applications. The collaboration combines Gurit's BondPro adhesive technology with medmix's MIXPAC™ greenLine™ cartridge system, targeting multiple sectors including automotive, transportation, industrial, construction, and agriculture.
The partnership leverages Gurit's expertise in high-performance adhesives and medmix's leadership in sustainable dispensing technology. This initiative aligns with medmix's broader strategy to invest in responsible solutions across its business operations, reinforcing its position in sustainable dispensing technology while expanding access to advanced bonding solutions globally.
medmix (SIX: MEDX) reported H1 2025 results showing improved profitability despite revenue challenges. Revenue declined to CHF 225.4 million (-6.5% YoY), with Healthcare segment growing 7.5% while Consumer & Industrial segment declined 10.9% organically.
Key financial metrics include adjusted EBITDA margin of 19.9% (+80 bps YoY), segment gross profit margin improvement of 390 bps to 47.9%, and Free Cash Flow of CHF 11.4m (+50.9% YoY). The company's Growth and Efficiency program secured CHF 15 million in savings, with CHF 8.5m realized in H1 2025.
Management revised 2025 revenue guidance to expect a decline similar to H1 2025, while maintaining adjusted EBITDA margin guidance of 18-19%. Mid-term guidance remains unchanged with revenue CAGR above 4% and adjusted EBITDA margin above 20%.
medmix (MDMXF) has achieved a significant environmental milestone by being named one of only nine Swiss companies to receive an "A" score in CDP's annual climate change assessment. The company also earned an "A-" score for water security, placing it among Switzerland's environmental leaders including Novartis, ABB, Swisscom, and Georg Fischer. This achievement is particularly notable as only 2% of nearly 23,000 companies evaluated globally by CDP received an "A" score.
CEO René Willi emphasized the company's strategic commitment to environmental management and transparent reporting. medmix, headquartered in Baar, Switzerland, operates 14 production sites worldwide with approximately 2,700 employees and holds over 900 active patents in high-precision delivery devices for healthcare, consumer, and industrial markets.